Christopher Brett Primiano Sells 1,500 Shares of Karyopharm Therapeutics Inc. (KPTI) Stock
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) SVP Christopher Brett Primiano sold 1,500 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $12.00, for a total value of $18,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Christopher Brett Primiano also recently made the following trade(s):
- On Friday, September 15th, Christopher Brett Primiano sold 2,000 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $11.00, for a total value of $22,000.00.
- On Tuesday, August 29th, Christopher Brett Primiano sold 2,195 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $10.00, for a total value of $21,950.00.
Karyopharm Therapeutics Inc. (KPTI) traded down 0.93% on Wednesday, hitting $11.67. The stock had a trading volume of 100,192 shares. The company’s 50 day moving average is $10.13 and its 200-day moving average is $9.84. The firm’s market capitalization is $550.10 million. Karyopharm Therapeutics Inc. has a 1-year low of $6.27 and a 1-year high of $14.63.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.64) earnings per share for the quarter, hitting the consensus estimate of ($0.64). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%. During the same period in the previous year, the business earned ($0.84) EPS. The company’s revenue was down 95.0% on a year-over-year basis. On average, analysts forecast that Karyopharm Therapeutics Inc. will post ($2.67) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Christopher Brett Primiano Sells 1,500 Shares of Karyopharm Therapeutics Inc. (KPTI) Stock” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/10/04/christopher-brett-primiano-sells-1500-shares-of-karyopharm-therapeutics-inc-kpti-stock.html.
Institutional investors have recently modified their holdings of the stock. Voya Investment Management LLC grew its stake in shares of Karyopharm Therapeutics by 42.1% in the second quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock worth $136,000 after purchasing an additional 4,444 shares during the last quarter. Tudor Investment Corp ET AL bought a new stake in shares of Karyopharm Therapeutics in the second quarter worth $136,000. American International Group Inc. grew its stake in shares of Karyopharm Therapeutics by 20.9% in the first quarter. American International Group Inc. now owns 16,422 shares of the company’s stock worth $211,000 after purchasing an additional 2,836 shares during the last quarter. Trexquant Investment LP bought a new stake in shares of Karyopharm Therapeutics in the second quarter worth $202,000. Finally, State of Wisconsin Investment Board bought a new stake in shares of Karyopharm Therapeutics in the second quarter worth $235,000. 58.97% of the stock is currently owned by institutional investors.
Several research analysts have issued reports on the company. BidaskClub downgraded Karyopharm Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 31st. ValuEngine downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 31st. Royal Bank Of Canada assumed coverage on Karyopharm Therapeutics in a report on Thursday, September 14th. They set an “outperform” rating and a $14.00 price objective on the stock. Zacks Investment Research raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a report on Thursday, July 6th. Finally, Cantor Fitzgerald set a $18.00 price objective on Karyopharm Therapeutics and gave the stock a “buy” rating in a report on Saturday, June 24th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. Karyopharm Therapeutics presently has an average rating of “Buy” and an average target price of $15.67.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.